SSI efficacy in treating infectious colitis

Inflammatory bowel disease (IBD) is a disease with unknown etiology that is characterized by uncontrolled intestinal inflammation and microbial dysbiosis. Qu Biologics’ Site Specific Immunomodulators (SSI) are a platform technology shown to improve the status of people living with IBD (Crohn’s disease and ulcerative colitis), with most of those patients showing clinical improvement also going into clinical remission. SSI are a complex biologic designed to reconstitute normal innate immune function through multiple parallel mechanisms. To better understand how SSI protect against IBD, we will test the efficacy of SSI in models of infectious colitis in collaboration with Dr. Bruce Vallance at the University of British Columbia.

Faculty Supervisor:

Bruce Vallance

Student:

Partner:

Qu Biologics

Discipline:

Life Sciences

Sector:

Biotechnology; Pharmaceuticals; Health and Related Sciences & Technology

University:

The University of British Columbia

Program: